3 European Penny Stocks With Market Caps Under €400M

Simply Wall St

Thu, December 11, 2025 at 1:05 AM EST 4 min read

As European markets navigate a landscape of mixed returns and inflationary pressures, investors are keeping a close eye on potential interest rate adjustments in the U.S. and UK. Amid these broader economic trends, penny stocks continue to capture attention for their unique investment opportunities. While the term ‘penny stocks’ may seem outdated, it still signifies smaller or newer companies that can offer significant growth potential when backed by strong financials. Let’s explore several examples of such stocks that stand out for their financial strength and potential for future gains.

Click here to see the full list of 279 stocks from our European Penny Stocks screener.

Let’s explore several standout options from the results in the screener.

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Cellectis S.A. is a clinical-stage biotechnology company focused on developing gene-editing products, including allogeneic chimeric antigen receptor T-cells for immuno-oncology and gene therapy candidates for various therapeutic applications, with a market cap of €309.91 million.

Operations: Cellectis generates its revenue primarily from its Therapeutics segment, which accounts for $82.55 million.

Market Cap: €309.91M

Cellectis S.A., a clinical-stage biotech company, has been making strides in gene-editing technologies with its recent publication on the use of circular single-stranded DNA (CssDNA), which shows promise for non-viral gene therapy applications. Despite being unprofitable, Cellectis has managed to reduce losses over the past five years and reported improved earnings in its latest quarter. The company maintains more cash than debt, providing a solid financial footing. However, it faces challenges such as high share price volatility and ongoing legal disputes over patent infringements related to its TALENs technology.

• Click here to discover the nuances of Cellectis with our detailed analytical financial health report.

• Learn about Cellectis’ future growth trajectory here.

Simply Wall St Financial Health Rating: ★★★★★☆